Altarum Institute, 3520 Green Court Suite 300, Ann Arbor, MI 48105, USA.
Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):361-70. doi: 10.1586/erp.13.23.
To present a generalized model to evaluate health and economic outcomes of targeted drug therapies and associated companion diagnostic tests with two applications.
An analytical model and derivatives applied to a nonlinear equation representing the costs and benefits of targeted therapy and associated companion diagnostics is developed. Economic analysis is then applied to a breast and colorectal cancer application with a multiparameter sensitivity analysis.
The generalized model readily facilitates trade-off analysis between, for example, alternative diagnostic test strategy cost and performance, and accounts for alternative therapy costs and benefits. Example applications demonstrate test performance and therapy costs and benefits are generally more critical parameters relative to diagnostic test cost.
While obtaining accurate data on therapy cost and benefits, test performance remains a key challenge in these analyses, the model presents key trade-offs and priorities for research to obtain more accurate clinical and economic information.
提出一种通用模型，通过两个应用程序来评估靶向药物治疗和相关伴随诊断测试的健康和经济结果。
开发了一种分析模型和衍生模型，应用于代表靶向治疗和相关伴随诊断的成本和收益的非线性方程。然后，对乳腺癌和结直肠癌应用进行经济分析，并进行多参数敏感性分析。
该通用模型便于在例如替代诊断测试策略成本和性能之间进行权衡分析，并考虑了替代治疗的成本和收益。示例应用表明，测试性能和治疗成本与收益通常相对于诊断测试成本更为关键的参数。
虽然获得了关于治疗成本和收益的准确数据，但在这些分析中，测试性能仍然是一个关键挑战，该模型提出了关键的权衡和研究重点，以获得更准确的临床和经济信息。
